105 related articles for article (PubMed ID: 3489799)
1. [Induction of tumoricidal effectors from the tumor-bearer's splenocytes and the prospects of their utilization for adoptive immunotherapy].
Takagi H; Okuno K; Nakamura T; Kokudo S; Iwasa Z; Yasutomi M
Nihon Gan Chiryo Gakkai Shi; 1986 May; 21(4):721-7. PubMed ID: 3489799
[No Abstract] [Full Text] [Related]
2. [Injection of interleukin-2 (IL-2) into the tumor-bearer's spleen augments lymphokine-activated killer (LAK) activity in vitro and inhibits tumor metastasis].
Okuno K; Ohnishi H; Takagi H; Nakamura T; Kokudo S; Yasutomi M
Nihon Geka Gakkai Zasshi; 1987 Jul; 88(7):802-7. PubMed ID: 3499562
[TBL] [Abstract][Full Text] [Related]
3. [Induction of lymphokine-activated killer (LAK) cells from tumor-bearer splenocytes and their utilization in inhibition of tumor metastasis].
Okuno K; Nakamura T; Takagi H; Kokudo S; Iwasa Z; Yasutomi M
Nihon Gan Chiryo Gakkai Shi; 1985 Oct; 20(9):2055-62. PubMed ID: 3879262
[No Abstract] [Full Text] [Related]
4. [LAK-adoptive immunotherapy with cytapheresis].
Urushizaki I
Rinsho Ketsueki; 1988 Nov; 29(11):1965-72. PubMed ID: 3266257
[No Abstract] [Full Text] [Related]
5. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
[TBL] [Abstract][Full Text] [Related]
6. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
[No Abstract] [Full Text] [Related]
7. [Using LAK cells in the adoptive immunotherapy in cancers].
Urushizaki I
Rinsho Ketsueki; 1987 Oct; 28(10):1897-8. PubMed ID: 3502569
[No Abstract] [Full Text] [Related]
8. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
Ujiie T
Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy of parenchymal tumors. Recent progress and theoretical considerations].
Marincola F; Smolik L; Annoni F; Holter WD
Minerva Chir; 1988 Jul; 43(13-14):1111-31. PubMed ID: 3054627
[No Abstract] [Full Text] [Related]
10. Soluble glucan and lymphokine-activated killer (LAK) cells in the therapy of experimental hepatic metastases.
Sherwood ER; Williams DL; McNamee RB; Jones EL; Browder IW; Di Luzio NR
J Biol Response Mod; 1988 Apr; 7(2):185-98. PubMed ID: 3283299
[TBL] [Abstract][Full Text] [Related]
11. [A new method of adoptive immunotherapy of a murine tumor with acid treatment: specific removal of major histocompatibility complex class I].
Fujii M; Konn M; Yamanaka Y; Odagiri H; Morita T; Sasaki M; Ono K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2879-81. PubMed ID: 3489443
[No Abstract] [Full Text] [Related]
12. Adoptive immunotherapy in gastrointestine malignancies using interleukin-2. Current results and future prospects.
Marshall GD
Acta Chir Scand Suppl; 1989; 549():71-4. PubMed ID: 2784605
[No Abstract] [Full Text] [Related]
13. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
14. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
[TBL] [Abstract][Full Text] [Related]
15. "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
Sondel PM; Hank JA; Kohler PC; Chen BP; Sosman J
Prog Clin Biol Res; 1989; 288():151-60. PubMed ID: 2654949
[No Abstract] [Full Text] [Related]
16. Natural killer cells.
Herberman RB
Prog Clin Biol Res; 1989; 288():161-7. PubMed ID: 2470107
[No Abstract] [Full Text] [Related]
17. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
Kan N; Okino T; Nakanishi M; Sato K; Mise K; Teramura Y; Yamasaki S; Hori T; Ohgaki K; Tobe T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
[TBL] [Abstract][Full Text] [Related]
18. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
19. [Successful adoptive immunotherapy with OK432-inducible activated natural killer cells on tumor-bearing mice].
Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K
Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2546-55. PubMed ID: 2614190
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
